+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

CAR T-Cell Therapy for Multiple Myeloma - Market Insight, Epidemiology and Market Forecast -2032

  • ID: 5010954
  • Report
  • January 2022
  • Region: Global
  • 200 Pages
  • DelveInsight

FEATURED COMPANIES

  • Bluebird bio/Celgene
  • CARsgen Therapeutics
  • Cartesian Therapeutics
  • Celgene Corporation
  • MolMed S.p.A.
  • Poseida Therapeutics
This "CAR T-Cell Therapy for Multiple Myeloma- Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the CAR T-Cell Therapy for Multiple Myeloma, historical and forecasted epidemiology as well as the CAR T-Cell Therapy for Multiple Myeloma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The CAR T-Cell Therapy for Multiple Myeloma market report provides current treatment practices, emerging drugs, CAR T-Cell Therapy for Multiple Myeloma market share of the individual therapies, current and forecasted CAR T-Cell Therapy for Multiple Myeloma market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current CAR T-Cell Therapy for Multiple Myeloma treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2019-2032

CAR T-Cell Therapy for Multiple Myeloma Disease Understanding and Treatment Algorithm


The CAR T-Cell Therapy for Multiple Myeloma market report gives a thorough understanding of the CAR T-Cell Therapy for Multiple Myeloma by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment.

Diagnosis


This segment of the report covers the detailed diagnostic methods or tests for CAR T-Cell Therapy for Multiple Myeloma.

Treatment


It covers the details of conventional and current medical therapies available in the CAR T-Cell Therapy for Multiple Myeloma market for the treatment of the condition. It also provides CAR T-Cell Therapy for Multiple Myeloma treatment algorithms and guidelines in the United States, Europe, and Japan.

CAR T-Cell Therapy for Multiple Myeloma Epidemiology


The CAR T-Cell Therapy for Multiple Myeloma epidemiology division provide insights about historical and current CAR T-Cell Therapy for Multiple Myeloma patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings


The disease epidemiology covered in the report provides historical as well as forecasted CAR T-Cell Therapy for Multiple Myeloma epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.

Country Wise- CAR T-Cell Therapy for Multiple Myeloma Epidemiology


The epidemiology segment also provides the CAR T-Cell Therapy for Multiple Myeloma epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

CAR T-Cell Therapy for Multiple Myeloma Drug Chapters


Drug chapter segment of the CAR T-Cell Therapy for Multiple Myeloma report encloses the detailed analysis of CAR T-Cell Therapy for Multiple Myeloma marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the CAR T-Cell Therapy for Multiple Myeloma clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Marketed Drugs


The report provides the details of the marketed product available for CAR T-Cell Therapy for Multiple Myeloma treatment.

CAR T-Cell Therapy for Multiple Myeloma Emerging Drugs


The report provides the details of the emerging therapies under the late and mid-stage of development for CAR T-Cell Therapy for Multiple Myeloma treatment.

CAR T-Cell Therapy for Multiple Myeloma Market Outlook


The CAR T-Cell Therapy for Multiple Myeloma market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted CAR T-Cell Therapy for Multiple Myeloma market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a thorough detail of CAR T-Cell Therapy for Multiple Myeloma market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to the publisher, CAR T-Cell Therapy for Multiple Myeloma market in 7MM is expected to change in the study period 2019-2032.

Key Findings


This section includes a glimpse of the CAR T-Cell Therapy for Multiple Myeloma market in 7MM.

The United States Market Outlook


This section provides the total CAR T-Cell Therapy for Multiple Myeloma market size and market size by therapies in the United States.

EU-5 Countries: Market Outlook


The total CAR T-Cell Therapy for Multiple Myeloma market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.

Japan Market Outlook


The total CAR T-Cell Therapy for Multiple Myeloma market size and market size by therapies in Japan is also mentioned.

CAR T-Cell Therapy for Multiple Myeloma Drugs Uptake


This section focusses on the rate of uptake of the potential drugs recently launched in the CAR T-Cell Therapy for Multiple Myeloma market or expected to get launched in the market during the study period 2019-2032. The analysis covers CAR T-Cell Therapy for Multiple Myeloma market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

CAR T-Cell Therapy for Multiple Myeloma Pipeline Development Activities


The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses CAR T-Cell Therapy for Multiple Myeloma key players involved in developing targeted therapeutics.

Pipeline Development Activities


The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for CAR T-Cell Therapy for Multiple Myeloma emerging therapies.

Reimbursement Scenario in CAR T-Cell Therapy for Multiple Myeloma


Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL-Views


To keep up with current market trends, we take KOLs and SME's opinion working in CAR T-Cell Therapy for Multiple Myeloma domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or CAR T-Cell Therapy for Multiple Myeloma market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis


The publisher performs Competitive and Market Intelligence analysis of the CAR T-Cell Therapy for Multiple Myeloma Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

  • The report covers the descriptive overview of CAR T-Cell Therapy for Multiple Myeloma, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
  • Comprehensive insight has been provided into the CAR T-Cell Therapy for Multiple Myeloma epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for CAR T-Cell Therapy for Multiple Myeloma are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of CAR T-Cell Therapy for Multiple Myeloma market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global CAR T-Cell Therapy for Multiple Myeloma market

Report Highlights

  • In the coming years, CAR T-Cell Therapy for Multiple Myeloma market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market

The companies and academics are working to assess challenges and seek opportunities that could influence CAR T-Cell Therapy for Multiple Myeloma R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition

Major players are involved in developing therapies for CAR T-Cell Therapy for Multiple Myeloma. Launch of emerging therapies will significantly impact the CAR T-Cell Therapy for Multiple Myeloma market

  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for CAR T-Cell Therapy for Multiple Myeloma
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

CAR T-Cell Therapy for Multiple Myeloma Report Insights

  • Patient Population
  • Therapeutic Approaches
  • CAR T-Cell Therapy for Multiple Myeloma Pipeline Analysis
  • CAR T-Cell Therapy for Multiple Myeloma Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

CAR T-Cell Therapy for Multiple Myeloma Report Key Strengths

  • 11 Years Forecast
  • 7MM Coverage
  • CAR T-Cell Therapy for Multiple Myeloma Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

CAR T-Cell Therapy for Multiple Myeloma Report Assessment


Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Questions Answered


Market Insights:

  • What was the CAR T-Cell Therapy for Multiple Myeloma market share (%) distribution in 2019 and how it would look like in 2032?
  • What would be the CAR T-Cell Therapy for Multiple Myeloma total market size as well as market size by therapies across the 7MM during the forecast period (2019-2032)?
  • What are the key findings pertaining to the market across 7MM and which country will have the largest CAR T-Cell Therapy for Multiple Myeloma market size during the forecast period (2019-2032)?
  • At what CAGR, the CAR T-Cell Therapy for Multiple Myeloma market is expected to grow in 7MM during the forecast period (2019-2032)?
  • What would be the CAR T-Cell Therapy for Multiple Myeloma market outlook across the 7MM during the forecast period (2019-2032)?
  • What would be the CAR T-Cell Therapy for Multiple Myeloma market growth till 2032, and what will be the resultant market Size in the year 2032?
  • How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

  • What is the disease risk, burden and unmet needs of the CAR T-Cell Therapy for Multiple Myeloma?
  • What is the historical CAR T-Cell Therapy for Multiple Myeloma patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of CAR T-Cell Therapy for Multiple Myeloma in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to CAR T-Cell Therapy for Multiple Myeloma?
  • Out of all 7MM countries, which country would have the highest prevalent population of CAR T-Cell Therapy for Multiple Myeloma during the forecast period (2019-2032)?
  • At what CAGR the population is expected to grow in 7MM during the forecast period (2019-2032)?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies:

  • What are the current options for the CAR T-Cell Therapy for Multiple Myeloma treatment, along with the approved therapy?
  • What are the current treatment guidelines for the treatment of CAR T-Cell Therapy for Multiple Myeloma in the USA, Europe, and Japan?
  • What are the CAR T-Cell Therapy for Multiple Myeloma marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
  • How many companies are developing therapies for the treatment of CAR T-Cell Therapy for Multiple Myeloma?
  • How many therapies are developed by each company for CAR T-Cell Therapy for Multiple Myeloma treatment?
  • How many are emerging therapies in mid-stage, and late stage of development for CAR T-Cell Therapy for Multiple Myeloma treatment?
  • What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the CAR T-Cell Therapy for Multiple Myeloma therapies?
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for CAR T-Cell Therapy for Multiple Myeloma and their status?
  • What are the key designations that have been granted for the emerging therapies for CAR T-Cell Therapy for Multiple Myeloma?
  • What are the global historical and forecasted market of CAR T-Cell Therapy for Multiple Myeloma?

Reasons to Buy

  • The report will help in developing business strategies by understanding trends shaping and driving the CAR T-Cell Therapy for Multiple Myeloma market
  • To understand the future market competition in the CAR T-Cell Therapy for Multiple Myeloma market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for CAR T-Cell Therapy for Multiple Myeloma in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for CAR T-Cell Therapy for Multiple Myeloma market
  • To understand the future market competition in the CAR T-Cell Therapy for Multiple Myeloma market
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Bluebird bio/Celgene
  • CARsgen Therapeutics
  • Cartesian Therapeutics
  • Celgene Corporation
  • MolMed S.p.A.
  • Poseida Therapeutics
1. Key Insights

2. Executive Summary of CAR T-Cell Therapy for Multiple Myeloma

3. Competitive Intelligence Analysis for CAR T-Cell Therapy for Multiple Myeloma

4. CAR T-Cell Therapy for Multiple Myeloma: Market Overview at a Glance
4.1. CAR T-Cell Therapy for Multiple Myeloma Total Market Share (%) Distribution in 2019
4.2. CAR T-Cell Therapy for Multiple Myeloma Total Market Share (%) Distribution in 2032

5. CAR T-Cell Therapy for Multiple Myeloma: Disease Background and Overview
5.1. Introduction
5.2. Sign and Symptoms
5.3. Pathophysiology
5.4. Risk Factors
5.5. Diagnosis

6. Patient Journey

7. CAR T-Cell Therapy for Multiple Myeloma Epidemiology and Patient Population
7.1. Epidemiology Key Findings
7.2. Assumptions and Rationale: 7MM
7.3. Epidemiology Scenario: 7MM
7.3.1. CAR T-Cell Therapy for Multiple Myeloma Epidemiology Scenario in the 7MM (2019-2032)
7.4. United States Epidemiology
7.4.1. CAR T-Cell Therapy for Multiple Myeloma Epidemiology Scenario in the United States (2019-2032)
7.5. EU-5 Country-wise Epidemiology
7.5.1. Germany Epidemiology
7.5.1.1. CAR T-Cell Therapy for Multiple Myeloma Epidemiology Scenario in Germany (2019-2032)
7.5.2. France Epidemiology
7.5.2.1. CAR T-Cell Therapy for Multiple Myeloma Epidemiology Scenario in France (2019-2032)
7.5.3. Italy Epidemiology
7.5.3.1. CAR T-Cell Therapy for Multiple Myeloma Epidemiology Scenario in Italy (2019-2032)
7.5.4. Spain Epidemiology
7.5.4.1. CAR T-Cell Therapy for Multiple Myeloma Epidemiology Scenario in Spain (2019-2032)
7.5.5. United Kingdom Epidemiology
7.5.5.1. CAR T-Cell Therapy for Multiple Myeloma Epidemiology Scenario in the United Kingdom (2019-2032)
7.5.6. Japan Epidemiology
7.5.6.1. CAR T-Cell Therapy for Multiple Myeloma Epidemiology Scenario in Japan (2019-2032)

8. Treatment Algorithm, Current Treatment, and Medical Practices
8.1. CAR T-Cell Therapy for Multiple Myeloma Treatment and Management
8.2. CAR T-Cell Therapy for Multiple Myeloma Treatment Algorithm

9. Unmet Needs

10. Key Endpoints of CAR T-Cell Therapy for Multiple Myeloma Treatment

11. Marketed Products
11.1. List of Marketed Products in the 7MM
11.2. Drug Name: Company Name
11.2.1. Product Description
11.2.2. Regulatory Milestones
11.2.3. Other Developmental Activities
11.2.4. Pivotal Clinical Trials
11.2.5. Summary of Pivotal Clinical Trial
List to be continued in report

12. Emerging Therapies
12.1. Key Cross
12.2. Drug Name: Company Name
12.2.1. Product Description
12.2.2. Other Developmental Activities
12.2.3. Clinical Development
12.2.4. Safety and Efficacy
12.2.5. Product Profile
List to be continued in report

13. CAR T-Cell Therapy for Multiple Myeloma: Seven Major Market Analysis
13.1. Key Findings
13.2. CAR T-Cell Therapy for Multiple Myeloma Market Size in 7MM
13.3. CAR T-Cell Therapy for Multiple Myeloma Market Size by Therapies in the 7MM

14. Attribute analysis

15. 7MM: Market Outlook
15.1. United States: Market Size
15.1.1. CAR T-Cell Therapy for Multiple Myeloma Total Market Size in the United States
15.1.2. CAR T-Cell Therapy for Multiple Myeloma Market Size by Therapies in the United States
15.2. EU-5 countries: Market Size and Outlook
15.3. Germany Market Size
15.3.1. CAR T-Cell Therapy for Multiple Myeloma Total Market Size in Germany
15.3.2. CAR T-Cell Therapy for Multiple Myeloma Market Size by Therapies in Germany
15.4. France Market Size
15.4.1. CAR T-Cell Therapy for Multiple Myeloma Total Market Size in France
15.4.2. CAR T-Cell Therapy for Multiple Myeloma Market Size by Therapies in France
15.5. Italy Market Size
15.5.1. CAR T-Cell Therapy for Multiple Myeloma Total Market Size in Italy
15.5.2. CAR T-Cell Therapy for Multiple Myeloma Market Size by Therapies in Italy
15.6. Spain Market Size
15.6.1. CAR T-Cell Therapy for Multiple Myeloma Total Market Size in Spain
15.6.2. CAR T-Cell Therapy for Multiple Myeloma Market Size by Therapies in Spain
15.7. United Kingdom Market Size
15.7.1. CAR T-Cell Therapy for Multiple Myeloma Total Market Size in the United Kingdom
15.7.2. CAR T-Cell Therapy for Multiple Myeloma Market Size by Therapies in the United Kingdom
15.8. Japan Market Outlook
15.8.1. Japan Market Size
15.8.2. CAR T-Cell Therapy for Multiple Myeloma Total Market Size in Japan
15.8.3. CAR T-Cell Therapy for Multiple Myeloma Market Size by Therapies in Japan

16. Access and Reimbursement Overview of CAR T-Cell Therapy for Multiple Myeloma

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix
20.1. Bibliography
20.2. Report Methodology

21. Publisher Capabilities

22. Disclaimer

23. About the Publisher
*The table of contents is not exhaustive; the final content may vary.

List of Tables
Table 1: 7MM CAR T-Cell Therapy for Multiple Myeloma Epidemiology (2019-2032)
Table 2: 7MM CAR T-Cell Therapy for Multiple Myeloma Diagnosed and Treatable Cases (2019-2032)
Table 3: CAR T-Cell Therapy for Multiple Myeloma Epidemiology in the United States (2019-2032)
Table 4: CAR T-Cell Therapy for Multiple Myeloma Diagnosed and Treatable Cases in the United States (2019-2032)
Table 5: CAR T-Cell Therapy for Multiple Myeloma Epidemiology in Germany (2019-2032)
Table 6: CAR T-Cell Therapy for Multiple Myeloma Diagnosed and Treatable Cases in Germany (2019-2032)
Table 7: CAR T-Cell Therapy for Multiple Myeloma Epidemiology in France (2019-2032)
Table 8: CAR T-Cell Therapy for Multiple Myeloma Diagnosed and Treatable Cases in France (2019-2032)
Table 9: CAR T-Cell Therapy for Multiple Myeloma Epidemiology in Italy (2019-2032)
Table 10: CAR T-Cell Therapy for Multiple Myeloma Diagnosed and Treatable Cases in Italy (2019-2032)
Table 11: CAR T-Cell Therapy for Multiple Myeloma Epidemiology in Spain (2019-2032)
Table 12: CAR T-Cell Therapy for Multiple Myeloma Diagnosed and Treatable Cases in Spain (2019-2032)
Table 13: CAR T-Cell Therapy for Multiple Myeloma Epidemiology in the UK (2019-2032)
Table 14: CAR T-Cell Therapy for Multiple Myeloma Diagnosed and Treatable Cases in the UK (2019-2032)
Table 15: CAR T-Cell Therapy for Multiple Myeloma Epidemiology in Japan (2019-2032)
Table 16: CAR T-Cell Therapy for Multiple Myeloma Diagnosed and Treatable Cases in Japan (2019-2032)
Table 17: Drug Name, Clinical Trials by Recruitment status
Table 18: Drug Name, Clinical Trials by Zone
Table 19: Total Seven Major Market Size in USD, Million (2019-2032)
Table 20: Region-wise Market Size in USD, Million (2019-2032)
Table 21: 7MM-Market Size by Therapy in USD, Million (2019-2032)
Table 22: United States Market Size in USD, Million (2019-2032)
Table 23: United States Market Size by Therapy in USD, Million (2019-2032)
Table 24: Germany Market Size in USD, Million (2019-2032)
Table 25: Germany Market Size by Therapy in USD, Million (2019-2032)
Table 26: France Market Size in USD, Million (2019-2032)
Table 27: France Market Size by Therapy in USD, Million (2019-2032)
Table 28: Italy Market Size in USD, Million (2019-2032)
Table 29: Italy Market Size by Therapy in USD, Million (2019-2032)
Table 30: Spain Market Size in USD, Million (2019-2032)
Table 31: Spain Market Size by Therapy in USD, Million (2019-2032)
Table 32: United Kingdom Market Size in USD, Million (2019-2032)
Table 33: United Kingdom Market Size by Therapy in USD, Million (2019-2032)
Table 34: Japan Market Size in USD, Million (2019-2032)
Table 35: Japan Market Size by Therapy in USD, Million (2019-2032)
*The list of tables is not exhaustive; the final content may vary

List of Figures
Figure 1: 7MM CAR T-Cell Therapy for Multiple Myeloma Epidemiology (2019-2032)
Figure 2: 7MM CAR T-Cell Therapy for Multiple Myeloma Diagnosed and Treatable Cases (2019-2032)
Figure 3: CAR T-Cell Therapy for Multiple Myeloma Epidemiology in the United States (2019-2032)
Figure 4: CAR T-Cell Therapy for Multiple Myeloma Diagnosed and Treatable Cases in the United States (2019-2032)
Figure 5: CAR T-Cell Therapy for Multiple Myeloma Epidemiology in Germany (2019-2032)
Figure 6: CAR T-Cell Therapy for Multiple Myeloma Diagnosed and Treatable Cases in Germany (2019-2032)
Figure 7: CAR T-Cell Therapy for Multiple Myeloma Epidemiology in France (2019-2032)
Figure 8: CAR T-Cell Therapy for Multiple Myeloma Diagnosed and Treatable Cases in France (2019-2032)
Figure 9: CAR T-Cell Therapy for Multiple Myeloma Epidemiology in Italy (2019-2032)
Figure 10: CAR T-Cell Therapy for Multiple Myeloma Diagnosed and Treatable Cases in Italy (2019-2032)
Figure 11: CAR T-Cell Therapy for Multiple Myeloma Epidemiology in Spain (2019-2032)
Figure 12: CAR T-Cell Therapy for Multiple Myeloma Diagnosed and Treatable Cases in Spain (2019-2032)
Figure 13: CAR T-Cell Therapy for Multiple Myeloma Epidemiology in the UK (2019-2032)
Figure 14: CAR T-Cell Therapy for Multiple Myeloma Diagnosed and Treatable Cases in the UK (2019-2032)
Figure 15: CAR T-Cell Therapy for Multiple Myeloma Epidemiology in Japan (2019-2032)
Figure 16: CAR T-Cell Therapy for Multiple Myeloma Diagnosed and Treatable Cases in Japan (2019-2032)
Figure 17: Drug Name, Clinical Trials by Recruitment status
Figure 18: Drug Name, Clinical Trials by Zone
Figure 19: Total Seven Major Market Size in USD, Million (2019-2032)
Figure 20: Region-wise Market Size in USD, Million (2019-2032)
Figure 21: 7MM-Market Size by Therapy in USD, Million (2019-2032)
Figure 22: United States Market Size in USD, Million (2019-2032)
Figure 23: United States Market Size by Therapy in USD, Million (2019-2032)
Figure 24: Germany Market Size in USD, Million (2019-2032)
Figure 25: Germany Market Size by Therapy in USD, Million (2019-2032)
Figure 26: France Market Size in USD, Million (2019-2032)
Figure 27: France Market Size by Therapy in USD, Million (2019-2032)
Figure 28: Italy Market Size in USD, Million (2019-2032)
Figure 29: Italy Market Size by Therapy in USD, Million (2019-2032)
Figure 30: Spain Market Size in USD, Million (2019-2032)
Figure 31: Spain Market Size by Therapy in USD, Million (2019-2032)
Figure 32: United Kingdom Market Size in USD, Million (2019-2032)
Figure 33: United Kingdom Market Size by Therapy in USD, Million (2019-2032)
Figure 34: Japan Market Size in USD, Million (2019-2032)
Figure 35: Japan Market Size by Therapy in USD, Million (2019-2032)
*The list of figures is not exhaustive; the final content may vary
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Bluebird bio/Celgene
  • CARsgen Therapeutics
  • Cartesian Therapeutics
  • Celgene Corporation
  • MolMed S.p.A.
  • Poseida Therapeutics

Multiple myeloma is a rare type of cancer that develops in plasma cells. The patients diagnosed with Multiple Myeloma, have cancer cells which are eventually overtake the healthy plasma cells. This process depletes the body of much-needed white blood cells.

A cure for Multiple Myeloma currently doesn't exist. However, significant research is making progressive leaps toward a treatment that eliminates the cancer entirely. None of the CAR T-cell therapies gained approval for Myeloma, however some of the late-stage potential therapies will impact the market in the near future.

Recent advancement in the upcoming therapies for Myeloma treatment with the development of CAR-T therapies will allow for greater availability of these approaches to patients. A number of new approaches are being explored to better optimize cellular therapies in myeloma.

Combinations with immunomodulatory drugs and checkpoint inhibitors may continue to enhance CAR T-cell activity, and clinical trials of these combinations are underway. The global Multiple Myeloma market is likely to be driven by the shift in the lifestyle of consumers and growing cases of plasma cancer across the globe. The rising penetration of cancer drugs including potential CAR-T therapies with their upcoming launch is expected to bode well for the growth of the global Multiple Myeloma market.


Multiple Myeloma Overview and use of CAR-T Cell Therapies Overview

Chimeric antigen receptor (CAR) T-cell therapy involves genetic modification of patient's autologous T-cells to express a CAR, specific for a tumor antigen, followed by ex vivo cell expansion and re-infusion back to the patient. CAR T-cells are the fusion proteins of a selected single-chain fragment variable from a specific monoclonal antibody and one or more T-cell receptor intracellular signalling domains.

A CAR combines antigen-binding domains-most commonly, a single-chain variable fragment (scFv) derived from the variable domains of antibodies with the signalling domains of the TCR chain and additional costimulatory domains from receptors, such as CD28, OX40, and CD137 (Morgenstern & Irwin, 2019).

T-cell genetic modification may occur either via viral-based gene transfer methods or non-viral methods, such as DNA-based transposons, CRISPR/Cas9 technology, zinc finger nuclease (ZFN), transcription activator-like effector nuclease (TALEN), or direct transfer of in vitro transcribed-mRNA by electroporation.

Multiple myeloma is a malignant proliferative disease of plasma cells. Clonal plasma cells producing immunoglobulin, proliferate and accumulate abnormally within the bone marrow, leading to hematopoietic insufficiency and lytic bone lesions. According to WHO, in 2018, 159,985 incident cases of multiple myeloma were reported in the world.

Though some substantial improvement measures have been implemented in the therapy of multiple myeloma, this disease still remains a highly incurable fatal hematopoietic malignancy for which potentially curative and safer novel treatments are required.

Multiple Myeloma Treatment

It covers the details of conventional and current therapy available in the Multiple Myeloma market for the treatment of the condition. It also provides the country-wise treatment guidelines and algorithm across the United States and Europe.

The Multiple Myeloma CAR T-Cell Therapy market report gives a thorough understanding of Multiple Myeloma by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Multiple Myeloma in the US and Europe.

Multiple Myeloma CAR T-Cell Therapy Chapters

CAR T-Cell Therapy chapter segment of the Multiple Myeloma report encloses the detailed analysis of Multiple Myeloma marketed Therapy and late stage (Phase-III and Phase-II) pipeline drugs based on CAR-T Cell therapies.. It also helps to understand the CAR T-Cell Therapy based clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included Therapy and the latest news and press releases for the treatment of Multiple Myeloma.

CAR T-Cell Based Emerging Therapies for Multiple Myeloma

bb2121: Bluebird bio/Celgene
bb2121 (also known as anti-BCMA CAR T-cells) is under development by Celgene (a BMS company) in collaboration with Bluebird bio. It is in phase III stage of development for the treatment of Multiple Myeloma.

Product details in the report.

Multiple Myeloma CAR T-Cell Therapy Market Outlook

The Multiple Myeloma CAR T-Cell Therapy market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted Multiple Myeloma CAR T-Cell Therapy market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a thorough detail of Multiple Myeloma CAR T-Cell Therapy market trend of each marketed Therapy and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.


  • According to the publisher, Multiple Myeloma CAR T-Cell Therapy market in 6MM is expected to change in the study period 2017-2030
  • Market Size of CAR T-Cell Therapy for Multiple Myeloma in the 6MM is expected to be USD 3,766.4 Million in 2030
  • Owing to the launch of upcoming therapies, market size shall increase during forecast period (2020-2030)
  • Among the EU-5 countries, the Germany, France, Italy accounts for highest market size for CAR T-Cell Therapy for Multiple Myeloma followed by UK and Spain

Multiple Myeloma CAR T-Cell Therapy Uptake

This section focuses on the rate of uptake of the potential CAR T-Cell Therapy expected to get launched in the market during the study period 2017-2030. The analysis covers Multiple Myeloma market uptake by CAR T-Cell therapies; patient uptake by therapies; and sales of each therapy.

This helps in understanding the CAR T-Cell Therapy with the most rapid uptake, reasons behind the maximal use of new CAR T-Cell Therapy and allows the comparison of the therapies on the basis of market share and Size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

CAR T-Cell Therapy Pipeline Development Activities for Multiple Myeloma
The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses CAR T-Cell Therapy key players involved in developing targeted therapeutics for Multiple Myeloma.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing and patent details for emerging CAR T-Cell Therapy for Multiple Myeloma.

Reimbursement Scenario in Multiple Myeloma CAR T-Cell Therapy

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In report we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business & price strategy.

KOL - Views

To keep up with current market trends, we take KOLs and SME's opinion working in CAR T-Cell Therapy for Multiple Myeloma domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Multiple Myeloma market trend. This will support the clients in potential upcoming novel CAR T-Cell Therapy for Multiple Myeloma treatment by identifying the overall scenario of the market and the unmet needs.


Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • Bluebird bio/Celgene
  • Janssen Research & Development
  • Poseida Therapeutics
  • MolMed S.p.A.
  • Celgene Corporation
  • Cartesian Therapeutics
  • CARsgen Therapeutics
  • Precision BioSciences
Note: Product cover images may vary from those shown